A High-Throughput RNA Displacement Assay for Screening SARS-CoV-2 nsp10-nsp16 Complex toward Developing Therapeutics for COVID-19. Read more about A High-Throughput RNA Displacement Assay for Screening SARS-CoV-2 nsp10-nsp16 Complex toward Developing Therapeutics for COVID-19.
The Kinase Chemogenomic Set (KCGS): An Open Science Resource for Kinase Vulnerability Identification. Read more about The Kinase Chemogenomic Set (KCGS): An Open Science Resource for Kinase Vulnerability Identification.
BET inhibition disrupts transcription but retains enhancer-promoter contact. Read more about BET inhibition disrupts transcription but retains enhancer-promoter contact.
Large-scale survey and database of high affinity ligands for peptide recognition modules. Read more about Large-scale survey and database of high affinity ligands for peptide recognition modules.
Inhibition of the SUV4-20 H1 histone methyltransferase increases frataxin expression in Friedreich's ataxia patient cells. Read more about Inhibition of the SUV4-20 H1 histone methyltransferase increases frataxin expression in Friedreich's ataxia patient cells.
Identification of small molecule allosteric modulators of 5,10-methylenetetrahydrofolate reductase (MTHFR) by targeting its unique regulatory domain. Read more about Identification of small molecule allosteric modulators of 5,10-methylenetetrahydrofolate reductase (MTHFR) by targeting its unique regulatory domain.
Development of a potent and selective chemical probe for the pleiotropic kinase CK2. Read more about Development of a potent and selective chemical probe for the pleiotropic kinase CK2.
Structure-kinetic relationship reveals the mechanism of selectivity of FAK inhibitors over PYK2. Read more about Structure-kinetic relationship reveals the mechanism of selectivity of FAK inhibitors over PYK2.
Drugging the 'undruggable' MYCN oncogenic transcription factor: Overcoming previous obstacles to impact childhood cancers. Read more about Drugging the 'undruggable' MYCN oncogenic transcription factor: Overcoming previous obstacles to impact childhood cancers.
Rational Design and Synthesis of Selective PRMT4 Inhibitors: a New Chemotype for Development of Cancer Therapeutics. Read more about Rational Design and Synthesis of Selective PRMT4 Inhibitors: a New Chemotype for Development of Cancer Therapeutics.
